RGI-2001: Phase I/II ongoing

Regimmune began the Phase II portion of an open-label, U.S. Phase I/II trial of IV RGI-2001 in leukemia patients given 30 minutes following allogeneic HSCT. The Phase I portion evaluated escalating do...